Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Clone 93 can be used for blocking of CD16/CD32 interactions with the Fc domain of immunoglobulins, but is not the same clone as 2.4G2.

The 93 mAb is specific to the common epitope of CD16/CD32. Additional reported applications (for the relevant formats) include: immunoprecipitation¹ and blocking of Fc-mediated reactions in functional studies^2,4,23. It is useful for blocking non-specific binding of immunoglobulin to Fc receptors. For blocking of Fc receptors in flow cytometric analysis, pre-incubate the cells with purified anti-CD16/CD32 antibody (=1.0 ?g per 10⁶ cells in 100 ?L volume) for 5-10 minutes on ice prior to immunostaining. For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 101330) (Endotoxin <0.01 EU/?g, Azide-Free, 0.2 ?m filtered).

BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.

1. Personal communication (IP)
2. Oliver AM, et al. 1999. Hybridoma 18:113. (Block)
3. Brummel R and Lenert P. 2005. J. Immunol. 174:2429.
4. Terrazas LI, et al. 2005. Int. J. Parasitol. 35:1349. (Block)
5. Clements JL, et al. 2006. J. Immunol. 177:905.
6. Mohamed W, et al. 2010. Infect Immun. 78:3306. PubMed
7. Ouchi T, et al. 2011. J. Exp Med. 208:2607. PubMed
8. Kmieciak M, et al. 2011. J. Vis. Exp. 47:2381. PubMed
9. Yamazaki S, et al. 2012. PLoS One. 7:e51665. PubMed
10. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
11. Azuma M, et al. 2012. Oncoimmunology. 1:581. PubMed
12. Koon HW, et al. 2013. J. Vis. Exp. 68:4208. PubMed
13. Hegde VL, et al. 2013. J Biol Chem. 288:36810. PubMed
14. Huang J, et al. 2013. J. Immunol Methods. 387:254. PubMed
15. Dutow P, et al. 2014. J Infect Dis. PubMed
16. Fan Y, et al. 2014. J Exp Med. 211:313. PubMed
17. Huang HN, et al. 2014. Antimicrob Agents Chemother. 58:1538. PubMed
18. Takei S, et al. 2014. Vaccine. 32:3066. PubMed
19. Richardson ML, et al. 2014. PLoS Negl Trop Dis. 8:2825. PubMed
20. Cekanaviciute E, et al. 2014. J Immunol. 193:139. PubMed
21. Kimura T, et al. 2014. Int Immunol. 26:697. PubMed
22. Everad A, et al. 2014. Nat Commun. 5:5648. PubMed
23. Cenci E, et al. 2006. J. Leuko. Biol. 79(1):40-5. (Block)

1. Hutter K, et al. 2022. Front Immunol. 13:967914. PubMed
2. Pathak JL, et al. 2021. Front Cell Dev Biol. 628139:9. PubMed
3. Ferrari de Andrade L, et al. 2020. Cancer Immunol Res. 0.867361111. PubMed
4. Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed
5. Domingues AF, et al. 2020. Elife. 9:e51754. PubMed
6. Bhattacharya Y 2014. J Exp Med. 211:841. PubMed
7. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
8. Li Z, et al. 2022. Elife. 11:. PubMed
9. McAlpine CS, et al. 2021. Nature. 595:701. PubMed
10. Pinho S, et al. 2022. Nat Cell Biol. 24:290. PubMed
11. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
12. Yamada D, et al. 2014. J Immunol. 192:4112. PubMed
13. Lu Q, et al. 2022. Biomed Res Int. 2022:9427076. PubMed
14. Woods B, et al. 2019. Clin Cancer Res. 25:5901. PubMed
15. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
16. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed

B cells, monocyte/macrophages, NK cells, neutrophils, mast cells, dendritic cells

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Unkeless JC. 1989. J. Clin. Invest. 83:355.
3. Qiu WQ, et al. 1990. Science 248:732.